Australia markets open in 5 hours 22 minutes

Checkpoint Therapeutics, Inc. (CZTA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.4480-0.0340 (-2.29%)
As of 08:03AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 52.55M
Enterprise value 47.96M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)269.13
Price/book (mrq)N/A
Enterprise value/revenue 465.61
Enterprise value/EBITDA -0.92

Trading information

Stock price history

Beta (5Y monthly) 0.93
52-week change 3-44.99%
S&P500 52-week change 322.38%
52-week high 33.0380
52-week low 31.2860
50-day moving average 31.7044
200-day moving average 31.8487

Share statistics

Avg vol (3-month) 3150
Avg vol (10-day) 3600
Shares outstanding 534.99M
Implied shares outstanding 638.08M
Float 828.74M
% held by insiders 17.87%
% held by institutions 114.67%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 306 Dec 2022

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-169,483.33%

Management effectiveness

Return on assets (ttm)-349.18%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)103k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-91.90%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-51.85M
Diluted EPS (ttm)-3.1800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.93M
Total cash per share (mrq)0.14
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.29
Book value per share (mrq)-0.47

Cash flow statement

Operating cash flow (ttm)-47.59M
Levered free cash flow (ttm)-43.27M